Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - pemetrexed disodium, quantity: 551.4 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; mannitol - malignant pleural mesothelioma:,pelimta, in combination with cisplatin, is indicated for the treatment of patients with malignant,pleural mesothelioma.,non-small cell lung cancer:,pelimta in combination with cisplatin is indicated for initial treatment of patients with locally,advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pelimta as monotherapy is indicated for the treatment of patients with locally advanced or,metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior,platinum-based chemotherapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - pemetrexed disodium - pdr/conc/soln for infus - 500 milligram(s) - antimetabolites

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - pemetrexed disodium - pdr/conc/soln for infus - 500 milligram - antimetabolites

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

seacross pharmaceuticals ltd - pemetrexed disodium - powder for solution for infusion - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

seacross pharmaceuticals ltd - pemetrexed disodium - powder for solution for infusion - 500mg

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - pemetrexed disodium heptahydrate, quantity: 699 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; mannitol - malignant pleural mesothelioma. alimta, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer. alimta in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

European Union - English - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - folic acid analogues, antineoplastic agents - malignant pleural mesothelioma pemetrexed medac in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed medac in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed medac is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed medac is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,

European Union - English - EMA (European Medicines Agency)

eli lilly netherlands - pemetrexed - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.pemetrexed lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.pemetrexed lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non small cell lung cancer other than predominantly squamous cell histology.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate -